Maze Therapeutics (MAZE) CSBO Atul Dandekar Exercises Options, Sells Shares

What Happened

• Atul Dandekar, Chief Scientific and Business Officer (CSBO) of Maze Therapeutics (MAZE), exercised 7,500 stock options on August 28, 2026 (acquired at $10.42 per share for a total cost of $78,150) and sold 7,500 shares in an open-market transaction the same day for a weighted-average price of $27.58 per share (total proceeds ~$206,824).
• The Form 4 also reports a conversion/disposition of 7,500 derivative shares at $0.00 on the same date (see Key Details for explanation). The activity resulted in an exercise followed by an immediate sale (a cashless-style outcome).

Key Details

• Transaction date: August 28, 2026; Form 4 filed August 31, 2026 (filing appears timely).
• Exercise: 7,500 options exercised at $10.42/share = $78,150.
• Sale: 7,500 shares sold at a weighted-average $27.58/share = $206,824; sales occurred at prices ranging $27.31–$28.01 (footnote confirms weighted average and offers to provide per-trade breakdown on request).
• Reported $0.00 disposition of 7,500 shares arising from an exercise/conversion (the filing does not state the purpose). $0 dispositions in exercises commonly reflect shares withheld or surrendered to cover taxes or exercise costs.
• Footnotes: sale executed under a Rule 10b5-1 trading plan adopted Sept 29, 2025; the related option award was fully vested as of March 17, 2025.
• Shares owned after the transactions are not specified in the provided filing excerpt.

Context

• This filing shows both an option exercise (acquisition) and an immediate sale (disposition). When insiders exercise and promptly sell shares, it often reflects liquidity/tax management rather than a clear buy or sell signal about company prospects.
• The sale was made under a pre-established 10b5-1 plan, which is a common mechanism that allows insiders to sell shares according to a preset schedule.